4
Clinical Trials associated with Trastuzumab biosimilar (Hisun Pharma)比较安瑞泽联合长春瑞滨与赫赛汀联合长春瑞滨治疗HER2阳性转移性乳腺癌的有效性、安全性和免疫原性的III期临床试验
[Translation] Phase III clinical trial comparing the efficacy, safety and immunogenicity of Anruiza combined with vinorelbine and Herceptin combined with vinorelbine in the treatment of HER2-positive metastatic breast cancer
比较安瑞泽®(HS022)+长春瑞滨与赫赛汀®+长春瑞滨治疗HER2阳性的转移性乳腺癌的有效性、安全性、免疫原性。
[Translation] To compare the efficacy, safety and immunogenicity of Anruiza® (HS022) + vinorelbine and Herceptin® + vinorelbine in the treatment of HER2-positive metastatic breast cancer.
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive breast cancer
Start Date16 May 2018 |
Sponsor / Collaborator- |
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety and Immunogenicity of Vinorelbine Bitartrate Injection in Combination With HS022 and Trastuzumab®.There were 2 parts. Part 1 needs 8 treatment cycles ( at least 24 weeks); Part2 needs 9 treatment cycles (at least 27 weeks).
100 Clinical Results associated with Trastuzumab biosimilar (Hisun Pharma)
100 Translational Medicine associated with Trastuzumab biosimilar (Hisun Pharma)
100 Patents (Medical) associated with Trastuzumab biosimilar (Hisun Pharma)
100 Deals associated with Trastuzumab biosimilar (Hisun Pharma)